Therapeutical areas

Proglumide, a weak gastrin receptor antagonist discovered by the Group early in the Seventies, has been the first non-cholinergic antisecretory agent to be used in the treatment of peptic ulcer, paving the way of more recent antisecretives (such as H2 blockers and proton pump inhibitors). The pharmacological properties of Proglumide, which included a gastroprotective effect, have been used to develop the NSAID Proglumetacin.
In the gastrointestinal/digestive area, Rottapharm has always been active in the development of drugs effective on gastrointestinal motility disorders: Tiropramide is a regulator of intestinal motility acting on the calcium-dependent contraction mechanisms of the visceral smooth muscle.
More recently, the potent and selective cholecystokinin (CCK) receptor antagonist, Loxiglumide and Dexloxiglumide, entered phase III clinical trials as potential agents for different gastrointestinal disorders, including irritable bowel syndrome and other gastrointestinal/digestive indications.

After Rottapharm' acquisition of Madaus Pharma (2007), Dexloxiglumide further development will merge with the ongoing clinical plans to expand the indications and range of formulations of Madaus' leading products for the treatment of constipation (Agiolax and Plantaben).

Gastroenterology/Hepatology

Rottapharm's R&D expertise in this therapeutic area will strongly benefit the ongoing clinical reasearch activities on Madaus world-wide known product Legalon for the treatment of chronic liver disease.

Such plans include an extensive clinical trial program with the US national Institute of Health (NIH).